---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-066738"
form_type: "8-K/A"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:18.283671+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger

## Summary
- Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.
- Pro forma combined net loss applicable to common shareholders: $1,894,119.
- Pro forma basic loss per share: $1.08; diluted loss per share: $1.08.
- Merger with ImmunogenX closed March 13, 2024; Entero is accounting acquirer.
- No changes to merger terms or business operations; filing purely supplemental.

## SEC filing metadata
- accession: 0001104659-24-066738
- form_type: 8-K/A
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/0001104659-24-066738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924066738/tm2416013d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-066738
- JSON: https://secwatch.observer/filing/0001104659-24-066738.json
- Plain text: https://secwatch.observer/filing/0001104659-24-066738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.